Summary
The plasma levels and myocardial content of verapamil and its metabolites norverapamil, N-dealkylverapamil and N-dealkylnorverapamil were determined in 15 patients with valvular [3] or ischaemic [12] heart disease. The mean myocardial plasma concentration ratio (M/P) was 7.05 for verapamil, 11.45 for norverapamil, 8.93 for N-dealkylverapamil, and 11.33 for N-dealkylnorverapamil, with great interpatient variability. The highest M/P ratios of verapamil were generally found in patients with the lowest plasma levels, suggesting that saturable tissue uptake may occur.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lewis JG (1983) Adverse reactions to calcium antagonists. Drugs 25: 196–222
Schütz E, Riem Ha H, Bühler FR, Follath F (1982) Serum concentration and antihypertensive effect of slow-release verapamil. J Cardiovasc Pharmacol 4 [Suppl 3]: 346–349
Storstein L, Midtbø K, Hals O, Myhre E (1981) Antihypertensive effect of verapamil in relation to plasma concentration of verapamil and its active metabolite norverapamil. Curr Ther Res 29: 112–119
Semplicini A, Pessina AC, Rossi GP, Padrini R, Tagliaferro R, Quintarelli GF, Ferrari M, Dal Palù C (1982) Plasma levels of verapamil and its effects on blood pressure, body fluid volumes and renal function in hypertensive patients. Int J Clin Pharmacol Res 2 [Suppl 1]: 81–86
Anderson P, Bondesson U, Sylven C, Åström H (1982) Plasma concentration-response relationship of verapamil in the treatment of angina pectoris. J Cardiovasc Pharmacol 4: 609–614
Frishman W, Kirsten E, Klein M, Pine P, Johnson SM, Hillis LD, Packer M, Kates R (1982) Clinical relevance of verapamil plasma levels in stable angina pectoris. Am J Cardiol 50: 1180–1184
Johnson A, Burgess CD, Hamer J (1981) Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol 12: 397–400
Dominic JA, Bourne DWA, Tan TG, Kirsten EB, McAllister RG Jr (1981) The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intavenous drug administration. J Cardiovasc Pharmacol 3: 25–38
Koike Y, Shimamura K, Shudo I, Saito H (1979) Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol 24: 37–47
Eichelbaum M, Birkel P, Grube E, Gütgeman U, Somogyi A (1980) Effects of verapamil on PR intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klin Wochenschr 58: 919–925
Reiter MJ, Shand DG, Pritchett ELG (1982) Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther 32: 711–720
McAllister RG, Kirsten EB (1982) The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 31: 418–426
Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M (1981) Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 12: 51–60
Keefe DL, Kates RE (1982) Myocardial disposition and cardiac pharmacodynamics of verapamil in the dog. J Pharmacol Exp Ther 220: 91–96
Harapat SR, Kates RE (1980) High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatogr 181: 484–489
Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automat Contr AC-19: 716–723
Hulthén UL, Landmann R, Bürgissen E, Bühler FR (1982) High affinity binding sites for (3H)verapamil in cardiac membranes. J Cardiovasc Pharmacol 4 [Suppl 3]: 291–293
Nayler WG (1983) The heterogeneity of the slow channel blockers (calcium antagonists). Int J Cardiol 3: 391–400
Neugebauer G (1978) Comparative cardiovascular actions of verapamil and its major metabolites in anaesthetized dog. Cardiovasc Res 12: 247–254
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Padrini, R., Barbieri, E., Piovan, D. et al. Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man. Eur J Clin Pharmacol 28, 653–657 (1985). https://doi.org/10.1007/BF00607910
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607910